CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
The CCTG Connection will be on hiatus until the Fall.
CCTG is very pleased to announce that Dr. Tim Whelan is the 2020 recipient of the CCTG Founder's Award - Dr. Joseph Pater Excellence in Clinical Trials Research.
This award honours an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This individual's research has provided techniques, information or concepts that will direct the future of the oncology research community and CCTG.
Two CCTG researchers were recently awarded nearly $2 million from the Canadian Cancer Society and the Conquer Cancer-Breast Cancer Research Foundation to support conduct of CCTG Investigational New Drug trials.
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for CCTG-Led trials has been awarded to the Princess Margaret Cancer Centre HN.10 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
CCTG is pleased to announce that the 2020 CCTG IND Team Award has been awarded to the BCCA Vancouver Centre IND.234 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
The team members include: Kim Chi, Manahil Sadiq, Julita Sienkiewicz, and Wendy Won.
CCTG is very pleased to announce that Dr. Dan Renouf has been awarded the CCTG Dr. Ralph Meyer Phase III Program Young Investigator Award.
This award honours young investigators who have contributed significantly on CCTG phase III projects with CCTG Disease Site Committees, Endpoint Committees, or Working Groups.
“I’m very honored to both be nominated for and to receive this award. The mentorship provided to me by many members within CCTG is very much appreciated," says Dr. Renouf.
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Princess Margaret Cancer Centre CE.8 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
CCTG is very proud to announce that Dr. Lillian Siu, Princess Margaret Cancer Centre, has been chosen as the recipient of the 2020 International Women Who Conquer Cancer Mentorship Award. Dr. Siu is the director of the Phase I Program, co-director of the Bras and Family Drug Development Program, and clinical lead for the Tumor Immunotherapy Program at Princess Margaret and is Co-Chair of CCTG's Head and Neck Site Committee. She also holds the BMO Chair in Precision Genomics.
